<?xml version='1.0' encoding='utf-8'?>
<document id="30257601"><sentence text="Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor." /><sentence text="GNE-617 (N-(4-((3,5-difluorophenyl)sulfonyl)benzyl)imidazo[1,2-a]pyridine-6-carboxamide) is a potent, selective nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being explored as a potential treatment for human cancers"><entity charOffset="0-87" id="DDI-PubMed.30257601.s2.e0" text="GNE-617 (N-(4-((3,5-difluorophenyl)sulfonyl)benzyl)imidazo[1,2-a]pyridine-6-carboxamide" /><entity charOffset="112-124" id="DDI-PubMed.30257601.s2.e1" text="nicotinamide" /><pair ddi="false" e1="DDI-PubMed.30257601.s2.e0" e2="DDI-PubMed.30257601.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30257601.s2.e0" e2="DDI-PubMed.30257601.s2.e1" /></sentence><sentence text=" Plasma clearance was low in monkeys and dogs (9" /><sentence text="14 mL min-1 kg-1 and 4" /><sentence text="62 mL min-1 kg-1, respectively) and moderate in mice and rats (36" /><sentence text="4 mL min-1 kg-1 and 19" /><sentence text="3 mL min-1 kg-1, respectively)" /><sentence text=" Oral bioavailability in mice, rats, monkeys and dogs was 29" /><sentence text="7, 33" /><sentence text="9, 29" /><sentence text="4 and 65" /><sentence text="2%, respectively" /><sentence text=" Allometric scaling predicted a low clearance of 3" /><sentence text="3 mL min-1 kg-1 and a volume of distribution of 1" /><sentence text="3 L kg-1 in human" /><sentence text=" Efficacy (57% tumor growth inhibition) in Colo-205 CRC tumor xenograft mice was observed at an oral dose of 15 mg/kg BID (AUC = 10" /><sentence text="4 µM h)" /><sentence text=" Plasma protein binding was moderately high" /><sentence text=" GNE-617 was stable to moderately stable in vitro"><entity charOffset="1-8" id="DDI-PubMed.30257601.s19.e0" text="GNE-617" /></sentence><sentence text=" Main human metabolites identified in human hepatocytes were formed primarily by CYP3A4/5" /><sentence text=" Transporter studies suggested that GNE-617 is likely a substrate for MDR1 but not for BCRP"><entity charOffset="36-43" id="DDI-PubMed.30257601.s21.e0" text="GNE-617" /></sentence><sentence text=" Simcyp® simulations suggested a low (CYP2C9 and CYP2C8) or moderate (CYP3A4/5) potential for drug-drug interactions" /><sentence text=" The potential for autoinhibition was low" /><sentence text=" Overall, GNE-617 exhibited acceptable preclinical properties and projected human PK and dose estimates" /><sentence text="" /></document>